NurExone Announces Corporate Updates

Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing

TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and the closing of a private placement.

Consulting Agreement with Former Bayer Scientist

The Company has signed a consulting agreement with Dr. Lars Bärfacker, an experienced medicinal chemist and former Principal Research Scientist at Bayer AG, to support aspects of NurExone’s European scientific and strategic initiatives. Dr. Bärfacker has more than two decades of experience in drug discovery and innovation and has contributed to the discovery of several clinical compounds, including Finerenone (Kerendia), now approved for the treatment of cardiorenal diseases.

NurExone CEO, Dr. Lior Shaltiel, noted: “Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications, including his experience at Bayer. His perspective will be valuable as NurExone continues advancing its regenerative medicine platform globally, particularly in Europe.”

Finalist at the BOLD Awards

NurExone has also been named a finalist in the Healthcare category of the 2026 BOLD Awards, an international program recognizing innovation and leadership across industries. The awards ceremony and networking events will take place in Barcelona, Spain, on March 27, 2026, with NurExone CEO Dr. Lior Shaltiel expected to attend.

Private Placement

The Company is also pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 1,295,222 units (“Units”) at a price of C$0.68 per Unit for aggregate gross proceeds of approximately $880,750.96 (the “Offering”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid in connection with this Offering.